BRAF (vemurafenib, dabrafenib and encorafenib) and MEK (trametinib, cobimetinib and binimetinib) inhibitors have proven to improve survival in BRAF-mutant unresectable or metastatic melanoma [35], although half of the patients develop resistance within a year [36]. The gene discussed is BRAF; the disease is metastatic melanoma.